Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Predictive Technology Group Finalizes Board Committee Chair Appointments

May 9, 2019

SALT LAKE CITY , May 09, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces Board of Director Committee Chair appointments.

Predictive’s Board of Directors, at its quarterly board meeting held May 8, 2019, finalized important committee appointments. Predictive Chairman of the Board John Sorrentino announced the following:

-- Audit Committee and Compliance Committee Chair is Jay Moyes -- Nominating Committee Chair is John Sorrentino -- Compensation Committee Chair is Ron Barhorst

“The Board made great strides in setting the future course of Predictive Technology Group by filling these important roles and welcoming new board members Senator Orrin Hatch, Jay Moyes and Ron Barhorst,” said Mr. Sorrentino.

About Predictive Technology Group, Inc.Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking StatementsTo the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.


For more information, visit www.predtechgroup.com or contact Investor Relations:

LHA Investor Relations Jody Cain jcain@lhai.com Kevin Mc Cabe kmccabe@lhai.com 310-691-7100